Page 47 - MemoriaEHD-Eng

www.ciberehd.org

• u e, s C, C e, r-C F, r-N J, s-L p .. Role
Most relevant LzurruNtepheNsrespouizaBeLLouizuñezaeNzópezet aL
of chemical structures and the 1331T>C bile salt export pump polymorphism in
scientific idiosyncratic drug-induced liver injury.Liver Int. 2013 Oct;33(9):1378-85.

articles
• Navarro-JaraBo JM, uBiña-azNar e, tapia-CeBaLLos L, ortiz-Cuevas C, pérez-aísa Ma, rivas-
ruiz F et aL.. Hepatic steatosis and severity-related factors in obese children.J Gas-

troenterol Hepatol. 2013 Sep;28(9):1532-8.

• aNDraDe rJ, garCía-saMaNiego J. [Biochemical and pharmacological features of telapre-
vir].Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:2-6.

• s C, L-N Má, r-C F, u e, s g, r-g M,
tepheNsópezevotuizaBeLLoLzurruNoriaNooMeroóMez
MoreNo-Casares a, LuCeNa Mi, aNDraDe rJ.. HLA alleles influence the clinical signature
of amoxicillin-clavulanate hepatotoxicity.Plos One. 2013;.

•
Highlights
5 PUBLIC COMPETITIVE RESEARCH PROJECTS (3 of the Sanitary Research
Fund (FIS).; 1 of the Andalusian Health Service; 1 of the Ministry of Economy,

Innovation and Science).

• 2 PRIVATE COMPETITIVE RESEARCH PROJECTS (AUIP grant (Asociación Uni-

versitaria Iberoamericana de postgrado) for the setting-up of an Ibero-Amer-
ican hepatotoxicity network. ;Grant from the University of Málaga (Research

commission) for the setting-up of Thematic networks, called: “Drug-Induced
Liver Injury”

•
2 CONTRACTS WITH COMPANIES (AGENCIA ESPAÑOLA DEL MEDICAMENTO;
BIOIBERICA S.A.).

• 3 EUROPEAN PROJECTS (Innovative Medicines Initiative. European Union.

Proposal acronym: PROTECT; Proyecto FLIP (SAS); SAFE-T INTERFACE EU-

ROPE).

AWARDS

• 6.000 € to the project: “Support of a multicentric and multidiciplinary Ibero-
American hepatotoxicity network induced by drugs and herbals products.”

Call of the Spanish Society of Digestive Pathology 2013.

PENDING PATENTS: 2.

• “Improved method to get meaningful data in predicting the fulminant hepatic

failure in DILI patients.” (Algorithm and Hy’s law).

Setting-up of an Ibero-American hepatotoxicity network.

In 2013, an Ibero-American hepatotoxicity registry was created. To date, infor-
mation from 114 DILI patients has been collected in Ibero-America.

Risk factors analisis that has an impact in developping the fulminant hepatic

failure in DILI patients. Published and presented in national and international 13
20
congresses.
T
OR
Analisis of anabolic steroids’ illicit use highlighting the necessity to control these P
compounds. Published and presented in national and international congresses.
RE
L
DILI analisis of autoinmune features.
A
NU
We analysed the combined effect on drug-induced liver injury (DILI) devel- N
A
opment of the ABCB11 1331T>C polymorphism and the presence of specific D /
chemical moieties, with known BSEP inhibiting properties, in the causative H
E
drug. Published in Liver Intern. 2013, Oct;33(9):1378-85.
ER
IB
C

47